Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYAxsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in MigrainePREV STORYMacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab